Group 1 - The stock price of Tongyuan Kang Pharmaceutical-B (02410) increased by over 6% during trading, with a current price of 13.14 HKD and a trading volume of 29.83 million HKD [1][6] - A clinical trial for the TEAD inhibitor TYK-01054 capsule has been initiated, focusing on its safety, tolerability, pharmacokinetics, and anti-tumor activity in patients with locally advanced or metastatic solid tumors [1][6] - The clinical trial is an I/II phase, open-label, multi-center study, with the registration number CTR20255003, and the first public information date is set for December 26, 2025 [1][6] Group 2 - TYK-01054 capsule is a chemical drug indicated for advanced solid tumors, which are characterized by cancer cells spreading to other parts of the body, with symptoms varying by tumor type, commonly including pain and fatigue [1][6] - Diagnosis of advanced solid tumors relies on imaging examinations and pathological biopsies [1][6]
同源康医药-B盘中涨超6% TYK-01054胶囊启动I/II期临床